PMID- 15307853
OWN - NLM
STAT- MEDLINE
DCOM- 20040917
LR  - 20160803
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 99
IP  - 8
DP  - 2004 Aug
TI  - The yield of upper gastrointestinal endoscopy in patients with suspected 
      reflux-related chronic ear, nose, and throat symptoms.
PG  - 1419-26
AB  - OBJECTIVES: It is well established that various ENT disorders and symptoms may be 
      a manifestation of gastroesophageal reflux disease (GERD). Erosive esophagitis is 
      considered a rare finding in ENT patients and therefore upper gastrointestinal 
      (GI) endoscopy is not recommended in the diagnostic work-up. However, large 
      prospective studies underscoring this policy are lacking. The aim of the present 
      study was to investigate the prevalence and severity of esophagitis in patients 
      with suspected GERD-related chronic ENT symptoms. METHODS: Endoscopy was 
      performed in 405 ENT patients with suspected GERD and 545 typical GERD patients. 
      The presence of erosive esophagitis, Barrett's esophagus, hiatal hernia, peptic 
      ulcer, and Helicobacter pylori infection on biopsies was determined and compared 
      with the results of a symptom questionnaire. RESULTS: The prevalence of erosive 
      esophagitis (52.3% vs 38.4%; p < 0.05), mainly grade 1 (31.9% vs 22.7%; p < 
      0.05), and of peptic ulcer (8.4% vs 4.3%; p < 0.05) was significantly higher in 
      patients with GERD-related ENT symptoms compared to typical GERD. Barrett's 
      mucosa occurred in, respectively, 4.9% and 4.5% of the patients (NS). Esophagitis 
      prevalence was highest in patients with predominant cough and lowest in globus 
      pharyngeus and throat symptoms. The presence of esophagitis was associated with 
      significantly higher rates of symptom relief during the first 8 wk of proton pump 
      inhibitor (PPI) therapy. CONCLUSIONS: Patients with suspected GERD-related ENT 
      symptoms have a high prevalence of esophagitis and this is associated with better 
      response to antisecretory therapy.
CI  - Copyright 2004 American College of Gastroenterology
FAU - Poelmans, Johan
AU  - Poelmans J
FAU - Feenstra, Louw
AU  - Feenstra L
FAU - Demedts, Ingrid
AU  - Demedts I
FAU - Rutgeerts, Paul
AU  - Rutgeerts P
FAU - Tack, Jan
AU  - Tack J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Ulcer Agents)
SB  - IM
CIN - Am J Gastroenterol. 2004 Aug;99(8):1427-9. PMID: 15307854
CIN - Am J Gastroenterol. 2005 Jun;100(6):1420; author reply 1420-1. PMID: 15929780
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Barrett Esophagus/diagnosis
MH  - Chronic Disease
MH  - Cough/etiology
MH  - Esophagitis, Peptic/diagnosis
MH  - *Esophagoscopy
MH  - Female
MH  - Gastroesophageal Reflux/*complications/*diagnosis/drug therapy
MH  - *Gastroscopy
MH  - Heartburn/etiology
MH  - Hernia, Hiatal/diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Otorhinolaryngologic Diseases/*etiology
MH  - Peptic Ulcer/diagnosis
MH  - Pharyngeal Diseases/etiology
EDAT- 2004/08/17 10:00
MHDA- 2004/09/21 05:00
CRDT- 2004/08/17 10:00
PHST- 2004/08/17 10:00 [pubmed]
PHST- 2004/09/21 05:00 [medline]
PHST- 2004/08/17 10:00 [entrez]
AID - AJG30066 [pii]
AID - 10.1111/j.1572-0241.2004.30066.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2004 Aug;99(8):1419-26. doi: 
      10.1111/j.1572-0241.2004.30066.x.